Clinical Trials
9 trialsNCT03589729 2026-05-22
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04188405 2026-05-22
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02115295 2026-05-20
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03263572 2026-05-20
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03326921 2026-05-18
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 1 Recruiting
NCT04877522 2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4 Recruiting
NCT03934372 2026-04-16
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
Phase 1/2 Recruiting
NCT01424982 2026-04-15
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07166419 2026-04-15
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting